panitumumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
human origin 4955 339177-26-3

Description:

MoleculeDescription

Synonyms:

  • panitumumab
  • vectibix
  • ABX-EGF
Recombinant human monoclonal antibody that binds to and inhibits the function of the EPIDERMAL GROWTH FACTOR RECEPTOR. It is used in the treatment of EGFR-expressing metastatic colorectal cancer that expresses wild-type ras gene (see GENES, RAS).
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Dec. 3, 2007 EMA Amgen Europe B.V.
Sept. 27, 2006 FDA AMGEN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dermatitis acneiform 972.71 27.11 209 9060 3848 50592007
Skin toxicity 490.83 27.11 119 9150 3794 50592061
Paronychia 482.59 27.11 121 9148 4443 50591412
Hypomagnesaemia 365.36 27.11 143 9126 23013 50572842
Dry skin 262.50 27.11 137 9132 43054 50552801
Stomatitis 213.02 27.11 164 9105 101180 50494675
Rash 206.39 27.11 320 8949 437151 50158704
Neutropenia 198.80 27.11 185 9084 147780 50448075
Disease progression 190.27 27.11 150 9119 95716 50500139
Skin fissures 174.38 27.11 64 9205 8604 50587251
Neuropathy peripheral 161.68 27.11 137 9132 96620 50499235
Diarrhoea 157.83 27.11 337 8932 588139 50007716
Rash pustular 119.87 27.11 45 9224 6436 50589419
Skin disorder 111.92 27.11 64 9205 23966 50571889
Metastases to liver 105.74 27.11 58 9211 20046 50575809
Neurotoxicity 101.70 27.11 51 9218 14689 50581166
Palmar-plantar erythrodysaesthesia syndrome 100.27 27.11 56 9213 20042 50575813
Skin reaction 91.68 27.11 44 9225 11524 50584331
Neutrophil count decreased 84.69 27.11 69 9200 45957 50549898
Mucosal inflammation 84.19 27.11 65 9204 40077 50555778
Peripheral sensory neuropathy 84.12 27.11 35 9234 6556 50589299
Thrombocytopenia 79.48 27.11 107 9162 127566 50468289
Drug ineffective 79.33 27.11 26 9243 819307 49776548
Xerosis 67.82 27.11 17 9252 620 50595235
Therapy partial responder 67.64 27.11 30 9239 6561 50589294
Hypertrichosis 64.62 27.11 18 9251 991 50594864
Polyneuropathy 61.03 27.11 34 9235 12097 50583758
Malignant neoplasm progression 59.94 27.11 68 9201 68056 50527799
Hypokalaemia 58.18 27.11 76 9193 87916 50507939
Acne 57.70 27.11 39 9230 19556 50576299
Hypocalcaemia 55.28 27.11 43 9226 26773 50569082
Trichomegaly 53.78 27.11 9 9260 37 50595818
Decreased appetite 53.16 27.11 115 9154 200808 50395047
Blood magnesium decreased 52.67 27.11 30 9239 11130 50584725
Febrile neutropenia 50.56 27.11 75 9194 97592 50498263
Dehydration 48.26 27.11 94 9175 152355 50443500
Colorectal cancer metastatic 46.25 27.11 12 9257 503 50595352
Anaemia 45.89 27.11 125 9144 252331 50343524
Erythema 44.79 27.11 89 9180 146325 50449530
Ileal perforation 44.51 27.11 11 9258 378 50595477
Leukopenia 42.57 27.11 57 9212 67471 50528384
Arthralgia 42.13 27.11 14 9255 438688 50157167
Carcinoembryonic antigen increased 41.56 27.11 14 9255 1460 50594395
Growth of eyelashes 41.08 27.11 9 9260 180 50595675
Death 38.65 27.11 139 9130 325240 50270615
Conjunctivitis 37.93 27.11 28 9241 16117 50579738
Fall 37.21 27.11 8 9261 334924 50260931
Ileus 35.80 27.11 25 9244 13204 50582651
Dermatitis 34.12 27.11 25 9244 14226 50581629
Pain of skin 33.88 27.11 20 9249 7927 50587928
Interstitial lung disease 33.68 27.11 45 9224 53131 50542724
Xeroderma 33.67 27.11 7 9262 108 50595747
Headache 32.69 27.11 27 9242 506508 50089347
Eye irritation 32.13 27.11 26 9243 17114 50578741
Gastrointestinal toxicity 31.71 27.11 16 9253 4661 50591194
Metastases to lung 30.22 27.11 21 9248 10999 50584856
Abdominal discomfort 29.06 27.11 4 9265 231637 50364218
Large intestine perforation 27.17 27.11 17 9252 7477 50588378

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dermatitis acneiform 1809.22 24.14 442 14481 5049 29554555
Paronychia 1018.83 24.14 247 14676 2706 29556898
Skin toxicity 828.57 24.14 220 14703 3551 29556053
Hypomagnesaemia 607.15 24.14 253 14670 17215 29542389
Rash 480.68 24.14 531 14392 189288 29370316
Skin reaction 349.08 24.14 117 14806 4300 29555304
Stomatitis 319.99 24.14 211 14712 36902 29522702
Rash pustular 318.88 24.14 111 14812 4580 29555024
Interstitial lung disease 296.80 24.14 240 14683 57478 29502126
Disease progression 246.38 24.14 252 14671 81664 29477940
Dry skin 236.65 24.14 147 14776 23160 29536444
Diarrhoea 221.81 24.14 504 14419 332194 29227410
Metastases to liver 213.71 24.14 109 14814 11747 29547857
Neutropenia 190.70 24.14 280 14643 131431 29428173
Neuropathy peripheral 189.32 24.14 205 14718 70822 29488782
Acne 184.49 24.14 91 14832 9129 29550475
Skin disorder 175.74 24.14 95 14828 11523 29548081
Folliculitis 150.55 24.14 61 14862 3839 29555765
Mucosal inflammation 134.49 24.14 118 14805 31477 29528127
Skin fissures 116.81 24.14 51 14872 3868 29555736
Conjunctivitis 111.53 24.14 62 14861 7936 29551668
Therapy partial responder 109.02 24.14 53 14870 5146 29554458
Decreased appetite 108.21 24.14 231 14692 145111 29414493
Drug ineffective 94.44 24.14 33 14890 363137 29196467
Metastases to lung 93.71 24.14 55 14868 7800 29551804
Carcinoembryonic antigen increased 93.53 24.14 27 14896 597 29559007
Neutrophil count decreased 89.37 24.14 110 14813 43457 29516147
Neurotoxicity 86.15 24.14 66 14857 14547 29545057
Xerosis 86.08 24.14 24 14899 466 29559138
Palmar-plantar erythrodysaesthesia syndrome 83.38 24.14 65 14858 14694 29544910
Hypocalcaemia 79.62 24.14 73 14850 20592 29539012
Polyneuropathy 74.08 24.14 56 14867 12096 29547508
Peripheral sensory neuropathy 71.93 24.14 42 14881 5897 29553707
Blood magnesium decreased 67.60 24.14 39 14884 5355 29554249
Drug interaction 58.38 24.14 14 14909 197371 29362233
Erythema 58.21 24.14 122 14801 75484 29484120
Thrombocytopenia 56.87 24.14 173 14750 134650 29424954
Dermatitis 56.74 24.14 40 14883 7758 29551846
Trichomegaly 54.62 24.14 10 14913 21 29559583
Headache 54.15 24.14 11 14912 173996 29385608
Ileus 51.84 24.14 49 14874 14353 29545251
Colorectal cancer metastatic 48.85 24.14 16 14907 545 29559059
Growth of eyelashes 46.93 24.14 10 14913 57 29559547
Dehydration 46.27 24.14 145 14778 114603 29445001
Arthralgia 45.18 24.14 8 14915 139609 29419995
Pulmonary embolism 43.93 24.14 110 14813 76424 29483180
Metastases to lymph nodes 42.39 24.14 26 14897 3991 29555613
Metastases to pelvis 41.66 24.14 12 14911 263 29559341
Perioral dermatitis 40.97 24.14 10 14913 112 29559492
Hepatectomy 40.28 24.14 9 14914 66 29559538
Intestinal obstruction 40.01 24.14 49 14874 19228 29540376
Catheter site thrombosis 39.49 24.14 8 14915 34 29559570
Metastases to peritoneum 36.45 24.14 17 14906 1503 29558101
Carbohydrate antigen 19-9 increased 36.42 24.14 10 14913 183 29559421
Somnolence 36.19 24.14 3 14920 93952 29465652
Febrile neutropenia 34.00 24.14 129 14794 112111 29447493
Fall 33.98 24.14 24 14899 177154 29382450
Gastrointestinal toxicity 33.81 24.14 18 14905 2113 29557491
Toxicity to various agents 32.68 24.14 24 14899 173637 29385967
Product dose omission issue 32.32 24.14 5 14918 96378 29463226
Livedo reticularis 31.34 24.14 17 14906 2071 29557533
Hypertrichosis 30.77 24.14 10 14913 332 29559272
Nail disorder 30.62 24.14 16 14907 1808 29557796
Ectropion 29.58 24.14 7 14916 68 29559536
Acne pustular 29.13 24.14 7 14916 73 29559531
Skin exfoliation 28.15 24.14 45 14878 22600 29537004
Epidermal naevus syndrome 27.82 24.14 5 14918 9 29559595
Dermatitis infected 27.58 24.14 7 14916 93 29559511
Overdose 27.08 24.14 4 14919 79815 29479789
Myocardial infarction 26.89 24.14 11 14912 110285 29449319
Dizziness 26.65 24.14 34 14889 189650 29369954
Eyelash changes 26.56 24.14 5 14918 13 29559591
Device related infection 26.56 24.14 36 14887 15600 29544004
Enterocolitis 26.54 24.14 24 14899 6642 29552962
Vena cava thrombosis 26.33 24.14 12 14911 1006 29558598
Cough 25.86 24.14 16 14907 126711 29432893
Cardiac failure congestive 25.61 24.14 4 14919 76577 29483027
Drug effective for unapproved indication 25.10 24.14 13 14910 1442 29558162
Confusional state 24.93 24.14 17 14906 127860 29431744
Myalgia 24.45 24.14 4 14919 74015 29485589

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dermatitis acneiform 2500.69 22.88 571 19917 7872 64470372
Paronychia 1268.50 22.88 314 20174 6178 64472066
Skin toxicity 1079.67 22.88 277 20211 6325 64471919
Hypomagnesaemia 751.63 22.88 321 20167 37055 64441189
Stomatitis 467.34 22.88 338 20150 109267 64368977
Rash 438.14 22.88 626 19862 457923 64020321
Disease progression 429.73 22.88 357 20131 141323 64336921
Dry skin 418.27 22.88 238 20250 50923 64427321
Neuropathy peripheral 393.89 22.88 314 20174 117211 64361033
Rash pustular 357.57 22.88 130 20358 9755 64468489
Interstitial lung disease 355.18 22.88 274 20214 97458 64380786
Neutropenia 327.41 22.88 391 20097 239233 64239011
Metastases to liver 299.41 22.88 148 20340 23793 64454451
Diarrhoea 298.58 22.88 685 19803 722019 63756225
Skin reaction 270.94 22.88 113 20375 12239 64466005
Skin disorder 251.16 22.88 138 20350 27542 64450702
Skin fissures 211.71 22.88 90 20398 10216 64468028
Acne 206.43 22.88 114 20374 22967 64455277
Therapy partial responder 192.46 22.88 84 20404 10164 64468080
Mucosal inflammation 185.72 22.88 156 20332 62428 64415816
Palmar-plantar erythrodysaesthesia syndrome 185.46 22.88 115 20373 28704 64449540
Neutrophil count decreased 166.96 22.88 161 20327 77035 64401209
Neurotoxicity 165.39 22.88 105 20383 27299 64450945
Thrombocytopenia 150.43 22.88 261 20227 223540 64254704
Decreased appetite 148.95 22.88 296 20192 280993 64197251
Polyneuropathy 142.39 22.88 85 20403 19809 64458435
Metastases to lung 127.21 22.88 72 20416 15192 64463052
Peripheral sensory neuropathy 117.92 22.88 62 20426 11316 64466928
Carcinoembryonic antigen increased 116.44 22.88 37 20451 1836 64476408
Drug ineffective 113.97 22.88 63 20425 840184 63638060
Conjunctivitis 110.53 22.88 73 20415 20281 64457963
Hypocalcaemia 109.44 22.88 97 20391 41656 64436588
Trichomegaly 92.21 22.88 17 20471 70 64478174
Hypertrichosis 89.61 22.88 27 20461 1121 64477123
Headache 85.22 22.88 31 20457 529436 63948808
Arthralgia 81.85 22.88 20 20468 442240 64036004
Xerosis 80.68 22.88 24 20464 953 64477291
Dermatitis 75.21 22.88 55 20433 17974 64460270
Ileus 73.79 22.88 60 20428 22906 64455338
Colorectal cancer metastatic 68.19 22.88 21 20467 939 64477305
Drug interaction 67.70 22.88 16 20472 362067 64116177
Fall 64.36 22.88 26 20462 416800 64061444
Leukopenia 61.32 22.88 113 20375 101129 64377115
Erythema 61.17 22.88 163 20325 186907 64291337
Febrile neutropenia 54.89 22.88 157 20331 187500 64290744
Blood magnesium decreased 50.39 22.88 39 20449 13866 64464378
Metastases to lymph nodes 49.10 22.88 32 20456 8685 64469559
Ectropion 48.58 22.88 13 20475 349 64477895
Pain 48.48 22.88 63 20425 553448 63924796
Malignant neoplasm progression 48.18 22.88 109 20379 112762 64365482
Carbohydrate antigen 19-9 increased 47.99 22.88 13 20475 366 64477878
Product dose omission issue 46.99 22.88 4 20484 194743 64283501
Hypokalaemia 46.88 22.88 113 20375 121790 64356454
Hepatectomy 46.56 22.88 11 20477 175 64478069
Peripheral swelling 46.10 22.88 6 20482 209147 64269097
Folliculitis 45.70 22.88 52 20436 30025 64448219
Intestinal obstruction 44.10 22.88 56 20432 36230 64442014
Gastrointestinal toxicity 44.05 22.88 25 20463 5297 64472947
Growth of eyelashes 43.99 22.88 10 20478 133 64478111
Toxicity to various agents 42.58 22.88 32 20456 363481 64114763
Depression 41.02 22.88 5 20483 183286 64294958
Death 40.53 22.88 277 20211 482428 63995816
Dermatitis infected 39.84 22.88 10 20478 207 64478037
Pulmonary embolism 39.47 22.88 119 20369 146237 64332007
Pain in extremity 39.06 22.88 24 20464 303061 64175183
Metastases to peritoneum 38.66 22.88 20 20468 3527 64474717
Somnolence 38.01 22.88 9 20479 203636 64274608
Nasopharyngitis 37.94 22.88 8 20480 196065 64282179
Confusional state 37.55 22.88 18 20470 261126 64217118
Ileal perforation 36.97 22.88 13 20475 883 64477361
Skin exfoliation 34.91 22.88 56 20432 44829 64433415
Product use issue 34.28 22.88 4 20484 151711 64326533
Cough 33.60 22.88 28 20460 302120 64176124
Dysgeusia 32.96 22.88 56 20432 46991 64431253
Perioral dermatitis 32.87 22.88 9 20479 264 64477980
Dizziness 32.68 22.88 54 20434 430109 64048135
Livedo reticularis 32.32 22.88 18 20470 3679 64474565
Mucocutaneous rash 32.11 22.88 6 20482 27 64478217
Hyperammonaemia 32.07 22.88 26 20462 9878 64468366
Thrombocytopenic purpura 31.95 22.88 15 20473 2147 64476097
Haematotoxicity 31.87 22.88 29 20459 12867 64465377
Metastases to pelvis 30.87 22.88 10 20478 528 64477716
Cardiac failure congestive 30.64 22.88 3 20485 130577 64347667
Epidermal naevus syndrome 30.13 22.88 5 20483 9 64478235
Overdose 29.88 22.88 7 20481 159559 64318685
Drug effective for unapproved indication 29.57 22.88 17 20471 3691 64474553
Gene mutation 29.40 22.88 14 20474 2068 64476176
Abdominal discomfort 28.70 22.88 11 20477 182311 64295933
Pain of skin 28.69 22.88 24 20464 9523 64468721
Musculoskeletal stiffness 28.46 22.88 3 20485 123203 64355041
Swelling 28.14 22.88 8 20480 160210 64318034
Device related infection 27.73 22.88 41 20447 30585 64447659
Drug hypersensitivity 27.73 22.88 21 20467 237794 64240450
Enterocolitis 27.71 22.88 26 20462 11992 64466252
Metastasis 27.50 22.88 19 20469 5676 64472568
Blepharitis 26.69 22.88 14 20474 2541 64475703
Nail disorder 26.58 22.88 22 20466 8602 64469642
Neoplasm progression 26.40 22.88 47 20441 40917 64437327
Colorectal cancer 26.31 22.88 15 20473 3206 64475038
Catheter site thrombosis 26.09 22.88 7 20481 190 64478054
Xeroderma 25.64 22.88 7 20481 203 64478041
Dehydration 25.53 22.88 136 20352 216627 64261617
Ascites 25.47 22.88 59 20429 61942 64416302
Drug intolerance 25.46 22.88 14 20474 187978 64290266
Eye irritation 25.08 22.88 28 20460 15828 64462416
Insomnia 25.01 22.88 16 20472 197820 64280424
Therapeutic product effect decreased 23.81 22.88 4 20484 115347 64362897
Venoocclusive liver disease 23.73 22.88 22 20466 9993 64468251
Pigmentation disorder 23.72 22.88 16 20472 4596 64473648
Bone marrow failure 23.51 22.88 49 20439 47903 64430341
Anxiety 23.49 22.88 18 20470 202631 64275613
Asthenia 23.48 22.88 223 20265 427821 64050423
Weight increased 23.42 22.88 20 20468 213328 64264916
Anaemia 23.17 22.88 202 20286 378478 64099766
Blood pressure increased 23.15 22.88 13 20475 172539 64305705

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01FE02 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
EGFR (Epidermal Growth Factor Receptor) inhibitors
FDA CS M0001357 Antibodies, Monoclonal
FDA MoA N0000020010 HER1 Antagonists
MeSH PA D000970 Antineoplastic Agents
MeSH PA D000074322 Antineoplastic Agents, Immunological
FDA EPC N0000175664 Epidermal Growth Factor Receptor Antagonist

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Secondary malignant neoplasm of colon indication 94260004




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Epidermal growth factor receptor Kinase AGONIST Kd 10.30 IUPHAR DRUG LABEL

External reference:

IDSource
D05350 KEGG_DRUG
4025701 VUID
N0000179714 NUI
4025701 VANDF
CHEMBL1201827 ChEMBL_ID
6883 IUPHAR_LIGAND_ID
8499 INN_ID
DB01269 DRUGBANK_ID
6A901E312A UNII
263034 RXNORM
22205 MMSL
88497 MMSL
d05879 MMSL
423259008 SNOMEDCT_US
424401006 SNOMEDCT_US
D000077544 MESH_DESCRIPTOR_UI
C0879427 UMLSCUI
011743 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Vectibix HUMAN PRESCRIPTION DRUG LABEL 1 55513-954 SOLUTION 100 mg INTRAVENOUS BLA 28 sections
Vectibix HUMAN PRESCRIPTION DRUG LABEL 1 55513-956 SOLUTION 400 mg INTRAVENOUS BLA 28 sections